
Sareum Holdings plc – LSE:SAR.L
Sareum Holdings stock price today
Sareum Holdings stock price monthly change
Sareum Holdings stock price quarterly change
Sareum Holdings stock price yearly change
Sareum Holdings key metrics
Market Cap | 34.16M |
Enterprise value | N/A |
P/E | -21 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 1257.54 |
Price/Book | 13.70 |
PEG ratio | 1.02 |
EPS | -0.09 |
Revenue | N/A |
EBITDA | -7.86M |
Income | -6.65M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -2088.62% |
Oper. margin | -2319.61% |
Gross margin | 0% |
EBIT margin | -2319.61% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSareum Holdings stock price history
Sareum Holdings stock forecast
Sareum Holdings financial statements
Jun 2021 | 0 | -953.38K | |
---|---|---|---|
Dec 2022 | 0 | -1.44M | |
Jun 2023 | 0 | -1.74M | |
Dec 2023 | 0 | -2.50M |
2026 | 43.14M | 25.86M | 59.95% |
---|
Analysts Price target
Financials & Ratios estimates
Jun 2021 | 3079176 | 284.15K | 9.23% |
---|---|---|---|
Dec 2021 | 5877000 | 198K | 3.37% |
Dec 2022 | 3345000 | 460K | 13.75% |
Dec 2023 | 1967000 | 489K | 24.86% |
Dec 2021 | -813K | -1K | 3.74M |
---|---|---|---|
Dec 2022 | -1.32M | 0 | 0 |
Jun 2023 | -1.90M | -41K | 0 |
Dec 2023 | -2.66M | 5K | 2.07M |
Sareum Holdings alternative data
Aug 2023 | 5 |
---|---|
Sep 2023 | 5 |
Oct 2023 | 5 |
Nov 2023 | 5 |
Dec 2023 | 5 |
Jan 2024 | 5 |
Feb 2024 | 5 |
Mar 2024 | 5 |
Apr 2024 | 5 |
May 2024 | 5 |
Jun 2024 | 5 |
Jul 2024 | 5 |
Sareum Holdings other data
Insider | Compensation |
---|---|
Dr. Tim J. Mitchell Ph.D. (1960) Founder, Chief Executive Officer & Executive Director | $189,410 |
Dr. John C. Reader Ph.D. (1967) Founder, Chief Scientific Officer & Executive Director | $187,010 |
-
What's the price of Sareum Holdings stock today?
One share of Sareum Holdings stock can currently be purchased for approximately $4.9.
-
When is Sareum Holdings's next earnings date?
Unfortunately, Sareum Holdings's (SAR.L) next earnings date is currently unknown.
-
Does Sareum Holdings pay dividends?
No, Sareum Holdings does not pay dividends.
-
How much money does Sareum Holdings make?
Sareum Holdings has a market capitalization of 34.16M.
-
What is Sareum Holdings's stock symbol?
Sareum Holdings plc is traded on the LSE under the ticker symbol "SAR.L".
-
What is Sareum Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sareum Holdings?
Shares of Sareum Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sareum Holdings's key executives?
Sareum Holdings's management team includes the following people:
- Dr. Tim J. Mitchell Ph.D. Founder, Chief Executive Officer & Executive Director(age: 65, pay: $189,410)
- Dr. John C. Reader Ph.D. Founder, Chief Scientific Officer & Executive Director(age: 58, pay: $187,010)
-
Is Sareum Holdings founder-led company?
Yes, Sareum Holdings is a company led by its founders Dr. Tim J. Mitchell Ph.D. and Dr. John C. Reader Ph.D..
-
How many employees does Sareum Holdings have?
As Jul 2024, Sareum Holdings employs 5 workers.
-
When Sareum Holdings went public?
Sareum Holdings plc is publicly traded company for more then 20 years since IPO on 11 Oct 2004.
-
What is Sareum Holdings's official website?
The official website for Sareum Holdings is sareum.com.
-
How can i contact Sareum Holdings?
Sareum Holdings can be reached via phone at +44 1223 497700.
Sareum Holdings company profile:

Sareum Holdings plc
sareum.comLSE
5
Biotechnology
Healthcare
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Cambridge, CB22 3FX
:
ISIN: GB00BMC3RJ87
CUSIP: G78173104